Retrospective feasibility study of Mycobacterium tuberculosis modified lipoprotein as a potential biomarker for TB detection in children

Preparation of malondialdehyde-conjugated LDL (MDA-LDL) (20) and Mtb-modified lipoprotein (TLP)

HepG2 human liver cells (ATCC HB-8065) were grown to 80% confluence in HepG2 growth media (DMEM, 10% fetal bovine serum, 20 mM L– glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10 mM HEPES). Cells were grown for 4-5 days and culture supernatants were then harvested and concentrated. LDL particles were separated by density gradient ultracentrifugation and desalted by ultrafiltration through a 100-kDa molecular weight filter. MDA-LDL was prepared by incubation 2 mg protein/mL of LDL with 2 μM acrolein at 37 °C for 24 h under nitrogen atmosphere. Mycobacterium tuberculosis was cultured in Middlebrook 7H9 (broth) supplemented with 0.2% glycerol, 0.5% BSA, 0.08% NaCl, 0.05% (v/v) tyloxapol to OD∼0.7. LDL was added and the culture was incubated at 37 °C for 7 days. TLP was isolated from the culture supernatant, concentrated and washed with PBS.

Agarose gel electrophoresis and western blot analysis

Agarose gel electrophoresis was performed in 0.06 M barbital buffer (pH 8.6). The gel was 0.8% and stained with Sudan Red 7B. Lipoproteins were separated on a 6% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), proteins were transferred to a PVDF membrane and immunoblotted with specific antibodies. The primary antibodies used for western blot were monoclonal anti-LDL (MDA oxidized) antibody (Abcam) and polyclonal anti-apoB Ab (H-300, Santa Cruz). Membranes were treated with anti-mouse, or anti-rabbit IgG HRP conjugates as secondary antibodies.

THP-1 macrophage preparation and treatment

THP-1 cells (ATCC TIB-202) were maintained in RPMI-1640 medium containing heat-inactivated 10% fetal bovine serum (FBS), 0.05 mM 2-mercaptoethanol, 100 U/mL penicillin and 100 mg/mL streptomycin (RPMI complete medium). The cells were plated into 6-well plates containing coverslips (1.5×10⁶ /well), treated with phorbol 12-myristate 13-acetate (PMA, 150 nM) in RPMI complete media. Media was replaced with fresh RPMI complete media at 48 hours after plating. At 72 hours after media change, THP-1 macrophages were treated with LDL, MDA-LDL and TLP at 200 μg/mL in PBS for 24 hours. All cells were incubated in a humid atmosphere at 37°C with 95% air and 5% CO₂.

Lipid body staining and immunostaining

Following lipoprotein treatment, macrophages were washed with PBS and fixed with 4% paraformaldehyde at room temperature for 30 minutes. Cells were stained with Oil Red O solution for 20 minutes at room temperature. The slides were then counterstained with haematoxylin and observed under an inverted microscope (Zeiss Axiovert 200M). Percent foam cell formation was quantified by counting stained versus total cells in 10 fields.

Generation of anti-TLP antibodies (22, 23)

Monoclonal antibodies against TLP were identified utilizing Human Combinatorial Antibody Library (HuCAL, Bio-Rad AbD Serotec GmbH). The HuCAL phage display library was depleted of antibodies that recognize intact LDL. The depleted library was panned for three rounds of binding, elution, and amplification to isolate antibodies specific for TLP. Binding of anti-TLP antibodies to control antigens including BSA, HSA, N1-CD33-His6 and intact LDL, was checked by indirect ELISA assays, with anti-TLP antibodies as primary antibodies and an anti-Fab-AP conjugate (Bio-Rad) as a secondary antibody.

Sandwich ELISA assay

Briefly, 96 well plates were coated overnight at 4°C with 5 μg/mL capture antibody (AbD28580, amino acid sequence shown in Table S2) in phosphate buffered saline (PBS). Plates were washed with PBS containing 0.05% Tween-20 (PBST) 3 times, blocked with 3% BSA in PBST for 1 hour at room temperature. Then serial dilutions of standards and test samples in HISPEC assay diluent (Bio-Rad) were loaded and allowed to react for 2 hours at room temperature. Plates were then washed 3 times with PBST and treated with 2 μg/mL of HRP conjugated detection antibody (AbD28582) in HISPEC assay diluent for 1 hour at room temperature. After washing 6 times with PBST, the plates were developed with QuantaBlu fluorogenic peroxidase substrate kit (Thermo Scientific) for 30 min at room temperature. Fluorescence was recorded (ex. 320 ± 25nm, em. 430 ± 35nm).

Subjects and samples

Retrospective analysis was performed on a total of 45 plasma samples from International Maternal Pediatric Adolescent AIDS Clinical Trails (IMPAACT) P1041 (24, 25). P1041 was a Phase II/ III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of isoniazid prophylaxis on TB disease and latent Mtb infection free survival in HIV-infected and HIV-exposed, but uninfected infants up to 192 weeks of follow up (25, 26). Samples include 24 with noTB and 21 with TBDIS, all HIV infected. Patients without Mtb infection were categorized as noTB; patients with a positive tuberculin skin test but lacking any clinical, radiographic or laboratory evidence of disease caused by Mtb were categorized as latent TB infection (LTBI); and patients presenting clinical, radiographic or laboratory evidence of disease caused by Mtb were categorized as TBDIS. Plasma samples were collected, frozen and thawed before use.

Statistical Analysis

Categorical variables were compared using t-student test, whenever appropriate. Non-parametric tests (Mann-Whitney) were used for non-normally distributed variables. Assay accuracy, including 95% confidence intervals, was assessed using sensitivity, specificity, predictive values and area under the ROC in the TB and non-TB groups. Statistical calculations were performed with GraphPad Prism® Software.

Mtb modified lipoprotein (TLP) is different from MDA-LDL

We purified and treated native LDL with Mycobacterium tuberculosis in vitro to obtain Mtb modified lipoprotein (TLP). Decreased mobility of TLP in agarose electrophoresis indicates that TLP is more positively charged than native LDL (Figure 1A). In contrast, MDA-LDL, one of the end products of lipid peroxidation, is more negatively charged than native LDL (20). The increased size of TLP compared to native LDL was also confirmed by dynamic light scattering analysis (Table S1). Furthermore, TLP is recognized by anti-apolipoprotein B (apoB) antibodies but not anti-MDA-LDL antibodies, indicating TLP does not contain a malondialdehyde-modified apoB derivative (Figure 1B). We demonstrate that LDL is altered in the presence of Mtb, and the resulting TLP is distinct from the typical atherosclerotic species malondialdehyde-modified LDL (MDA-LDL) present in human blood (27).

• Download figure
• Open in new tab

Figure 1. TLP is different from MDA-LDL.

(A) an agarose gel electrophoresis showing TLP is larger in size and more positively charged than native LDL. (B) Immunoblots showing TLP is recognized by anti-apolipoprotein B (apoB) antibodies (top) but not anti-MDA-LDL antibodies (bottom).

Mtb modified LDL induces lipid body accumulation in macrophages

The induction of foamy macrophages have been reported as hallmarks in many pathologies associated with chronic proinflammatory stimuli including atherosclerosis (15). It has also been reported that Mtb lipids induce the formation of giant multinuclear macrophages (28). We therefore used foamy macrophage formation as a tool to assess the bioactive components that trigger a tissue response similar to granuloma formation in TB. Lipid bodies were stained with Oil red O. The buffer control showed no accumulation of lipid bodies and the cells remained rounded (Figure 2A). LDL treated macrophage showed some lipid accumulation, with a commensurate increase in cell size (Figure 2B). In contrast, MDA-LDL, commonly associated with atherosclerosis, treated macrophages exhibited more extensive accumulation of lipid bodies than the LDL treated macrophages. These macrophage phenotypes are consistent with previous reports of in vitro foamy macrophage formation (20, 29). Most importantly, TLP treated macrophages had extensive lipid body accumulation per cell compared to macrophages treated with other LDLs (Figure 2 and S1B). Moreover, the TLP-treated macrophage morphology was distinct from other samples. The majority of the TLP-treated macrophages became multinucleated (Figure 2D and S1A) and developed long filopodia consistent with cell migration or exocytosis. Thus, we hypothesize that the modified LDL is detectable in vivo to serve as a biomarker for TB disease, and an antibody specific for recognition of TLP is an Mtb-specific indicator of infection and progression to (active) TB disease.

• Download figure
• Open in new tab

Figure 2. TLP induces lipid body accumulation in macrophages.

Microscopic images of Oil Red O-hematoxylin stained THP-1 macrophage culture treated with PBS control (A), LDL (B), MDA-LDL (C) and TLP (D) at 200 μg/mL for 2 days.

Anti-TLP monoclonal antibodies were generated and a TLP Sandwich ELISA assay was established

We generated 13 anti-TLP monoclonal antibodies (Fad-A-FH, bivalent Fab-bacterial alkaline phosphatase fusion antibody followed by FLAG^® and His6-tag) from the Human Combinatorial Antibody Library (HuCAL, Bio-Rad AbD Serotec GmbH) using in vitro selection and counter selection (22, 23). HuCAL is a phage display library containing highly specific, fully human monoclonal antibodies, with DNA sequence encoded for each antibody fragment. The HuCAL phage display library was depleted of antibodies that recognize LDL (Figure S2). The depleted library was panned for three rounds of binding, elution, and amplification to isolate antibodies specific for TLP. Among the antibody hits selected, 13 antibodies were identified as unique by DNA sequencing. These antibodies were produced heterologously for further development. The cross-reactivity with native LDL, human serum albumin, bovine serum albumin, and His₆ affinity tag was determined in an indirect ELISA format. Eight antibodies showed a specific signal for TLP at least 4-fold above native LDL background (Figure S2). We tested pairwise combinations of antibodies to identify antibody pairs that have non-overlapping epitopes suitable for use in a sandwich ELISA (Figure S3A). 5 sandwich pairs were identified with good signal over background and the assay conditions were optimized for the best pair, AbD28582 and AbD28580 (amino acid sequence shown in Table S2). We established the linear response of the sandwich ELISA (Figure S3B) to antigen spiked into pediatric plasma. TLP is specifically detected at >=4ppm in the presence of plasma LDL, which is around 10⁶ ng/mL (30).

Levels of TLP are increased in patients with active TB compared to no TB controls

We assayed stored plasma samples from the HIV IMPAACT P1041 trial for the presence of TLP. The median plasma levels of TLP was 494 ng/mL in control subjects, and 2.7 fold higher in active TB subjects (Figure 3A). The difference between control subjects and active TB subjects is significant (p<0.001). The receiver operating characteristic (ROC) analysis describes the relationship between the sensitivity and specificity at any cut-off values. An ROC curve of TLP concentration for active TB versus control subjects is presented in Figure 3B. The area under the ROC curve (AUC) is 0.86 (95% CI=0.75-0.97, p<0.0001). An optimal cutoff of 1064 ng/mL rendered 71% sensitivity and 88% specificity. Alternatively, a cutoff of 1230 ng/mL provided 57% sensitivity and of 96% specificity.

• Download figure
• Open in new tab

Figure 3. Retrospective analysis of P1041 HIV positive plasma samples.

(A) Plasma levels of TLP in HIV positive subjects clinically diagnosed probably having active stage tuberculosis disease (TB) and not having TB (noTB). Individual patients are depicted as dots with group mean. The dashed line represents the detection limit of the assay. *** p<0.001. (B) ROC curve of TLP concentration for active TB versus control subjects of HIV positive patients. AUC, area under curve. The dashed line represents the no-discrimination line from the left bottom to the top right corners.

We also monitored apoB levels, i.e., LDL levels, of all the samples using Human apoB ELISA kits (ab190806, Abcam) and found there was no linear correlation between TLP and apoB levels (Figure S5A), suggesting that plasma LDL fluctuation does not interfere with TLP detection. There is a weak correlation between TLP levels and time before or after diagnosis (Figure S5). The samples collected before diagnosis may represent disease progression from no infection or infection but without clinical signs of disease to outward manifestation of disease. Samples collected after diagnosis may represent a mixed outcome of disease progression and anti-tubercular treatment. We do not have additional sample sets to demonstrate if anti-tubercular treatment affects TLP levels. However, the discrimination of TLP levels between control subjects and active TB subjects (post diagnosis with treatment less than 40 weeks) was improved with the exclusion of samples collected after 40 weeks of treatment (p<0.0001), which may represent patients clear of TB. ROC (Receiver operating characteristic) analysis provided an AUC (area under the ROC curve) of 0.88 (95% CI=0.76-0.99, p<0.0001). An optimal cutoff of 632 ng/mL gave 67% sensitivity and 93% specificity. The results provide further evidence that TLP levels are associated with active TB disease. Overall, the results clearly highlight the potential of TLP as a biomarker in the diagnosis of active TB in HIV positive child.